Celon Pharma’s key medicines maintain strong market shares

…in net profit to PLN 13.4m (€3m) and a 21% drop in total revenue to PLN 57m (€13m) in H1 2017. However, the year-ago figures were boosted by PLN 12.7m (€3m) worth of milestone payments for distribution rights to Salmex on foreign markets and so are not directly comparable.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.